LifeMD(US:LFMD) Prnewswire·2025-09-06 13:12Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [3][4]. Group 1: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position [3]. - It is claimed that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. - As a result, statements made by the defendants regarding LifeMD's business and prospects were materially false and misleading [3]. Group 2: Financial Impact - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from a previous guidance of $268 to $275 million [4]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [4]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The deadline to seek the role of lead plaintiff in the federal securities class action against LifeMD is October 27, 2025 [1].